Could a common drug make head and neck cancer treatment more effective?
NCT ID NCT06997094
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing the safety and best dose of the drug decitabine when added to standard surgery, radiation, and chemotherapy for people with HPV-negative head and neck cancer that can be surgically removed. Decitabine may help make cancer cells more sensitive to standard treatments. The study involves 24 participants and aims to find the highest safe dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Decitabine
What this could lead to
If successful, this could make standard treatments like chemotherapy and radiation more effective for HPV-negative head and neck cancer, potentially improving survival.
What could go wrong
This is an early phase I trial with only 24 participants, focused on safety and dosing. It may not lead to a proven treatment, and decitabine can cause serious side effects like low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS-NEGATIVE NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••